PPG’s New Paint for a New Start initiative to beautify schools worldwide with colorful makeovers
7.6.2023 15:00:00 EEST | Business Wire | Press release
PPG (NYSE:PPG) today announced that it will dedicate June, July and August 2023 to completing more than 25 colorful and transformative school makeovers worldwide through its New Paint for a New Start initiative, part of the company’s COLORFUL COMMUNITIES® program.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230607005072/en/
In June, July and August 2023, PPG employees worldwide will transform learning environments and create transformative school makeovers through the New Paint for a New Start initiative. (Photo: Business Wire)
In the second year of New Paint for a New Start, PPG employees will volunteer their time to transform learning environments. Using PPG paint products and color expertise, each project aims to create engaging spaces for students to learn and grow.
“PPG employees from every region are coming together once again to protect and beautify schools and learning spaces and inspire bright starts for students,” said Malesia Dunn, executive director, PPG Foundation and Corporate Global Social Responsibility. “For young students, every day is an opportunity for a new start to learn, grow and develop in a positive learning environment. We are aiming to help them start each day with a positive outlook and create joyful spaces where they feel supported and engaged.”
New in 2023, PPG volunteers are building on the impact that new paint and improved learning environments have on students and teachers by reaching new markets, teaming up with PPG customer partners and activating PPG Employee Resource Networks.
“New Paint for a New Start provides students and school infrastructures in need with meaningful changes and resources for fresh starts. This extends to inspiring students to have greater environmental consciousness,” said Diane Kappas, PPG vice president, Global Sustainability, and New Paint for a New Start executive champion. “In 2023, we’re also incorporating an element of sustainability into each project, including activities such as recycling materials and supplies, planting trees, environmentally themed murals, and educational activities.”
Most of the transformation projects will use a global color palette that PPG color experts specifically selected to elevate and enhance the physical classroom environments.
In addition to painting spaces, PPG and the PPG Foundation are also supplying several New Paint for a New Start schools with funding for science, technology, engineering and mathematics (STEM) supplies.
Last year, more than 1,000 PPG volunteers and community partners took part in New Paint for a New Start, dedicating 6,400 hours to transform classrooms and learning spaces for more than 23,000 students and educators. Learn more here.
The Colorful Communities program, PPG’s signature initiative for supporting communities, aims to protect and beautify the neighborhoods where PPG operates around the world. Through the Colorful Communities program, PPG’s committed volunteers contribute their time and PPG paint products to help transform community assets – from painting classrooms to bringing color to a maternity ward and redesigning a playground. Since 2015, PPG has completed more than 470 Colorful Communities projects, impacting more than 8.2 million people in 50 countries.
PPG’s global community engagement efforts and the PPG Foundation aim to bring color and brightness to PPG communities around the world. We invested $16.2 million in 2022, supporting hundreds of organizations across more than 35 countries. By investing in educational opportunities, we help grow today’s skilled workforce and develop tomorrow’s innovators in fields related to coatings and manufacturing. Plus, we empower PPG employees to multiply their impact for causes that are important to them by supporting their volunteer efforts and charitable giving. Learn more at communities.ppg.com.
PPG: WE PROTECT AND BEAUTIFY THE WORLD®
At PPG (NYSE:PPG), we work every day to develop and deliver the paints, coatings and specialty materials that our customers have trusted for 140 years. Through dedication and creativity, we solve our customers’ biggest challenges, collaborating closely to find the right path forward. With headquarters in Pittsburgh, we operate and innovate in more than 70 countries and reported net sales of $17.7 billion in 2022. We serve customers in construction, consumer products, industrial and transportation markets and aftermarkets. To learn more, visit www.ppg.com.
Colorful Communities, the PPG Logo and We protect and beautify the world are registered trademarks of PPG Industries Ohio, Inc.
CATEGORY Community Affairs
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230607005072/en/
Contact information
PPG Media Contact:
Mark Silvey
Corporate Communications
+1 412 434 3046
silvey@ppg.com
www.ppgcommunities.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 11:16:00 EEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom